

Case Study

Biosceptre – UK, Australia, UAE




Biosceptre is a leading biopharmaceutical company focused on providing new therapies for a wide range of cancer patients. Its researchers work on cell-therapy and immune-oncology treatment and have made significant discoveries to help target cancer cells more effectively.

The company is headquartered in Cambridge, UK, and has operating subsidiary companies in Sydney, Australia, and Dubai in the UAE. Kreston firm PEM in Cambridge was appointed as Biosceptre's UK advisers when the company restructured its operations and set up in the UK during 2013. PEM has been providing a broad range of services since, including audit, accounts, tax compliance, payroll R&D tax credit claims and share incentive plans.

Biosceptre's Sydney operation had been using non-Kreston advisers but felt it was not receiving the level of service it required. Its management team met with Kreston Stanley Williamson in 2020 and appointed the firm as their Australian advisers. Kreston Awni Farsakh & Co were appointed when Biosceptre's subsidiary in Dubai was incorporated the year before.

Gary Faull, CFO at Biosceptre, said: "The Kreston Global network has been very responsive to our needs for local tax advice and audit services. As we have expanded and grown internationally, they have provided both local and global services in a seamless and integrated way. Thanks for the great support!"

The Kreston Global teams involved co-ordinate their work to ensure Biosceptre receives consistently high-quality services across their operations. The Life Sciences expertise within the network means the advice provided is both timely and on point.



Our services to Biosceptre have adapted as the group has grown, and the Kreston Global network has proved ideal for the company. It is a multi-national company needing multi-national advisers. The company benefits from improved levels of service and likes the way the Kreston Global firms work together. We look forward to supporting them further in the coming years.



Callum Dunsmore
Director at PEM